Italy’s Stevanato Group has entered an exclusive agreement with medical device developer Owen Mumford in a bid to streamline the production of the Aidaptus auto-injector.
With the deal, Stevanato Group becomes an exclusive manufacturing partner for the auto-injector.
The Italian firm will mould the components for the device as well as deliver final and sub-assembly equipment. It will also offer pre-filled syringes to enable pharmaceutical customers to deliver the final product for patient use.
Stevanato Group will assemble Aidaptus components at its global manufacturing sites. Owen Mumford will also assemble the device at its automated assembly centre of excellence in the UK.
Stevanato Group chief business officer Mauro Stocchi said: “We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market.
“As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities, being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems.”
A two-step single-use auto-injector, Aidaptus can accommodate 1ml and 2.25ml prefilled glass syringes in the same base device.
It is equipped with a self-adjusting plunger rod that can automatically adapt to multiple fill volume options without any changes to the device.
Additionally, Aidaptus can be used to administer drugs with different viscosities.
Owen Mumford director Adam Mumford said: “Aidaptus will help patients to self-administer their individual therapies using a simple and easy-to-use device.
“At the same time, this auto-injector can help reduce complexity, minimise supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies, thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes.”
Stevanato Group will demonstrate Aidaptus and its portfolio of integrated solutions at the Pharmapack Europe, Paris Expo in France, later this month.